AELIS FARMA

📢 We're #hiring a new Scientific Data Manager in Bordeaux, Nouvelle-Aquitaine. Apply today or share this post with your network.

🤝 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗔𝗲𝗹𝗶𝘀 𝗙𝗮𝗿𝗺𝗮’𝘀 𝗖𝗕𝟭-𝗦𝗦𝗶 𝗮𝘁 𝗕𝗶𝗼-𝗘𝘂𝗿𝗼𝗽𝗲 𝗙𝗮𝗹𝗹 𝗶𝗻 𝗦𝘁𝗼𝗰𝗸𝗵𝗼𝗹𝗺, 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟰-𝟲, 𝟮𝟬𝟮𝟰 Aelis Farma is pioneering a new pharmacological class, the CB1-SSi (Signaling Specific inhibitors of the CB1), the first and only safe CB1 inhibitors lacking adverse and psychiatric side effects. Book a meeting with the Aelis management team (Pier Vincenzo Piazza, Stéphanie Monlezun, Arsene Guekam) to discover our portfolio of distinct CB1-SSi with blockbuster potentials: 🔹 𝗔𝗘𝗙𝟬𝟭𝟭𝟳, for cannabis use disorders, proved pharmacologically active significantly decreasing cannabis intake in a phase 2A (Haney et al, 2023, Nat. Med.) and in a recent phase 2B 🔹 𝗔𝗘𝗙𝟬𝟮𝟭𝟳, targets a large spectrum of cognitive disorders, such as those of neurodevelopment, aging, Parkinson’s disease and schizophrenia. AEF0217 has shown an excellent safety profile in in healthy volunteers. The results of a phase1/2 in people with Down syndrome will be announced in Q4 2024 🔹 𝗡𝗲𝘄 𝗖𝗕𝟭-𝗦𝗦𝗶. Aelis proprietary platform has developed new CB1-SSi that will target: 1. Obesity and related metabolic diseases; and 2. Dopamine-dependent brain disorders such as ADHD Looking forward to meeting you at #BIOEurope to gain insights into our innovative pipeline and explore business opportunities 🚀 #AELIS #biotech #CB1 #CB1SSi #cannabis #cognition #downsyndrome #obesity #ADHD #neurosciences

𝗔𝗲𝗹𝗶𝘀 𝗙𝗮𝗿𝗺𝗮’𝘀 𝟮𝟬𝟮𝟰 𝗛𝗮𝗹𝗳-𝗬𝗲𝗮𝗿 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗶𝘁𝘀 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝗮𝗻𝗱 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝘂𝘁𝗹𝗼𝗼𝗸 𝗮𝗿𝗲 𝗼𝘂𝘁 👇 As of June 30, 2024, Aelis Farma had a solid cash position of €12.6 million, not including the gross amount of €4.5 million share offering which occurred at the end of July and other non-dilutive financing currently being obtained, ensuring financial visibility until the end of 2026. During the first half of 2024, Aelis Farma made significant progress with its two clinical stage drug-candidates and an expansion of its screening capabilities. Thus, this first semester was marked by: ☑ The last patient last visit in the Phase 2B trial with AEF0117 for the treatment of cannabis use disorders (CUD) in April 2024. Although the primary endpoint was not met the preliminary results of this study show a statistically significant decrease in cannabis consumption in participants with moderate CUD. ☑ The end of recruitment for a phase 1/2 study with AEF0217 in people with Down syndrome. The results of the study will be announced in Q4 2024. ☑ The expansion of research capabilities with the transfer of the screening laboratory responsible for identifying new CB1-SSi molecules to the IECB (Institut Européen de Chimie et de Biologie) in Pessac (Bordeaux).   #AELIS #biotech #cannabisaddiction #CB1 #downsyndrome #cognitiveimpairments #neurosciences #halfyearstatement

CB1-SSi, AELIS FARMA’ molecularly biased CB1 inhibitors, eliminate the side effects of CB1 antagonists.

𝗡𝗲𝘄𝘀! 𝗣𝗶𝗲𝗿 𝗩𝗶𝗻𝗰𝗲𝗻𝘇𝗼 𝗣𝗶𝗮𝘇𝘇𝗮 𝗶𝗻 𝗟𝗲 𝗝𝗼𝘂𝗿𝗻𝗮𝗹 𝗱𝗲𝘀 𝗕𝗶𝗼𝘁𝗲𝗰𝗵𝘀 Pier Vincenzo Piazza, CEO of Aelis Farma, was Laurent Grassin's guest on the BOURSORAMA show “Le Journal des Biotechs” to share preliminary findings and major takeaways of our pioneer phase 2b with AEF0117 in cannabis addiction. This trial allowed us to confirm that AEF0117 has an excellent safety profile and is pharmacologically active. Don’t miss this opportunity to hear from our CEO what these results mean for the future of AEF0117, our promising treatment in cannabis addiction, and the further validation of our new pharmacological class, the CB1-SSi (interview in french). #AELIS #biotech #cannabis #addiction #CUD #CB1receptor #neurosciences #cognition #downsyndrome

𝗦𝘂𝗺𝗺𝗮𝗿𝘆 𝗼𝗳 𝘁𝗵𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗼𝗳 𝗔𝗘𝗙𝟬𝟭𝟭𝟳 𝗣𝗵𝗮𝘀𝗲 𝟮𝗯 𝗶𝗻 𝗖𝗨𝗗 𝗚𝗲𝗻𝗲𝗿𝗮𝗹 𝗴𝗼𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝘀𝘁𝘂𝗱𝘆 The main goal of this pioneering phase 2B study was to demonstrate that AEF0117 reduces cannabis use in CUD patients and to determine the endpoints as well as the optimal dosage of AEF0117 to be used in future studies. To answer these questions, we conducted the largest and most rigorous study to date on cannabis use disorders (CUD), including 333 patients recruited across 11 clinical centers in the US. Quality control (QC) and analysis are still in process. Consequently, the following results and insights should be considered as preliminary. 𝗣𝗿𝗲𝗹𝗶𝗺𝗶𝗻𝗮𝗿𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀: ☑ AEF0117 is pharmacologically active, further validating the new CB1-SSi pharmacological class developed by Aelis. ☑ AEF0117 (1mg/day) did not meet its primary endpoint, a binary measure evaluating the increase in the proportion of patients using cannabis ≤1 day per week ☑ At the highest dose of AEF0117 (1mg/day), using a quantitative endpoint, a statistically significant reduction in cannabis use was observed in participants with moderate CUD. ☑ AEF0117 has an excellent safety profile without the side effects seen in the previous generation of CB1 antagonists. 𝗧𝗵𝗲 𝘀𝘁𝘂𝗱𝘆 𝗳𝘂𝗹𝗳𝗶𝗹𝗹𝗲𝗱 𝗶𝘁𝘀 𝗴𝗲𝗻𝗲𝗿𝗮𝗹 𝗴𝗼𝗮𝗹 𝗯𝘆 𝘀𝗵𝗼𝘄𝗶𝗻𝗴 𝘁𝗵𝗮𝘁: ☑ Quantitative endpoints seems more adapted than binary endpoints to study changes in cannabis use in CUD patients. ☑ It is likely that dose higher than 1 mg should be used in future studies, which is feasible given the excellent safety profile. 𝗡𝗲𝘅𝘁 𝘀𝘁𝗲𝗽𝘀: We are currently completing the QC and analysis of the data before determining the next regulatory and development steps that will be communicated once this process is completed. To learn more about our phase 2b results and AEF0117, watch the replay of our webinar showcased by Pier Vincenzo Piazza and Stéphanie Monlezun (CEO and COO of Aelis Farma).   #AELIS #biotech #cannabisaddiction #CB1 #neurosciences #cognition #downsyndrome

𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗗𝗮𝘆 𝗔𝗴𝗮𝗶𝗻𝘀𝘁 𝗗𝗿𝘂𝗴 𝗔𝗯𝘂𝘀𝗲 𝗮𝗻𝗱 𝗜𝗹𝗹𝗶𝗰𝗶𝘁 𝗧𝗿𝗮𝗳𝗳𝗶𝗰𝗸𝗶𝗻𝗴 By resolution 42/112 of 7 December 1987, the General Assembly of the United Nations decided to observe 26 June as the International Day against Drug Abuse and Illicit Trafficking as an expression of its determination to strengthen action and cooperation in achieving a world free of drug abuse. 𝗧𝗵𝗲 𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗶𝘀 𝗰𝗹𝗲𝗮𝗿: 𝗶𝗻𝘃𝗲𝘀𝘁 𝗶𝗻 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 At Aelis Farma, we believe that preventing addiction should include the early detection of drug use disorders to enhance treatment efficacy. Unfortunately, most individuals seek treatment for drug use disorders only when their condition has become severe, making treatment more challenging. Detecting mild drug use disorders and offering treatment at this early stage could be transformative in preventing the progression to addiction. At Aelis Farma, we are dedicated to developing impactful treatment solutions that can make a real difference in people's lives. Currently, we are fully committed to advancing our first drug candidate, AEF0117, for the treatment of cannabis use disorders (CUD). Stay tuned for the results of the phase 2b study of AEF0117 in CUD in Q3 2024. Let's use this day as an opportunity to come together, educate ourselves and others, and support those who may be struggling. Together, we can build healthier, happier communities. #WorldDrugDay #InvestInPrevention #AELIS #cannabis #CUD #addiction #SAMHSA #neurosciences #cognition #CB1

𝗣𝗶𝗲𝗿 𝗩𝗶𝗻𝗰𝗲𝗻𝘇𝗼 𝗣𝗶𝗮𝘇𝘇𝗮, 𝗖𝗘𝗢 𝗼𝗳 𝗔𝗲𝗹𝗶𝘀 𝗙𝗮𝗿𝗺𝗮, 𝗶𝗻 𝘁𝗵𝗲 𝗺𝗲𝗱𝗶𝗮! 👨⚕️ 🔬 Pier Vincenzo Piazza, CEO of Aelis Farma, interviewed exclusively by L'Express. This insightful conversation covers Aelis Farma's innovative approach to treat cannabis addiction, groundbreaking developments of the new pharmaceutical class of CB1-SSi and Pier Vincenzo Piazza's vision for the future of addiction. Don't miss out on this opportunity to learn more on cannabis addiction. Link to the article in comment 👇 #AELIS #biotech #cannabis #CUD #SAMHSA #neurosciences #cognition

AELIS FARMA’s AEF0117 pour l’addiction au cannabis Merci à BFMTV pour ce reportage

Aelis Farma Daycare Initiative has launched !!!! We are happy to contribute to more inclusive scientific conferences